GlassScriptPhysician profile
Estrella Aguinaldo
NPI 1548339278
$2,972.41
in general payments reported to CMS, 2019-2025
23 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $166 · 2021: $567 · 2022: $674 · 2023: $451 · 2024: $460 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $622.84 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $580.60 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $339.74 | 2020-2023 | Ozempic, Rybelsus |
| Amgen INC. | $260.44 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $226.78 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.10 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $144.97 | 2021-2024 | Jardiance, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $70.98 | 2023-2024 | Shingrix, Arexvy |
| Grt US Holding, INC. | $54.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.96 | 2022-2024 | Xifaxan |
| Abbott Laboratories | $48.03 | 2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $46.25 | 2019 | |
| Kaleo, INC. | $46.15 | 2019 | |
| Xeris Pharmaceuticals, INC. | $42.57 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $40.72 | 2024 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.81 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $25.79 | 2024 | |
| Avanir Pharmaceuticals, INC. | $22.29 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.93 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $18.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.42 | 2025 | Zoryve |
| Inogen, INC. | $8.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Estrella Aguinaldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.